Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Japanese encephalitis virus vaccine, inactivated · Ixiaro, IXIARO

Vaccine (Inactivated vaccine) · Immune activation, directed at Japanese encephalitis virus · developed by Valneva Austria GmbH

Approved FDA, Mar 2009

VALN Developer

2 Registered trials

What is Japanese encephalitis virus vaccine, inactivated?

IXIARO is an inactivated, adsorbed Japanese encephalitis vaccine given by intramuscular injection. It is directed at the Japanese encephalitis virus and is studied in Japanese encephalitis, including booster immunisation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Ixiaro, IXIARO
Drug type: Vaccine (Inactivated vaccine)
Targets: Japanese encephalitis virus (antigen)
Mechanism: Immune activation, directed at Japanese encephalitis virus
Therapy area: Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Approved as Ixiaro (March 30, 2009), BLA125280

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03971058	Phase 4	Japanese Encephalitis Vaccine	Unknown	VALN
NCT01296360	Phase 3	Japanese Encephalitis	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Japanese EncephalitisJapanese Encephalitis Vaccine

More from Valneva Austria GmbH

IC51 FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1553 Phase 3 VLA1601 Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind Japanese encephalitis virus vaccine, inactivated

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z